Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)

Author affiliations

Abstract

We have developed a co-assembled nanosystem based on fenofibrate and ketoprofen by tactfully utilizing their simultaneous benzophenone interaction, which greatly enhances the bioavailability of fenofibrate and plays a role in the dual-targeted treatment of NAFLD by reducing hepatic lipid accumulation and inflammatory responses.

Graphical abstract: Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)

Back to tab navigation

Supplementary files

Article information


Submitted
19 Jan 2020
Accepted
17 Mar 2020
First published
17 Mar 2020

Chem. Commun., 2020, Advance Article
Article type
Communication

Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD)

Z. Wang, C. Ma, Y. Shang, L. Yang, J. Zhang, C. Yang, C. Ren, J. Liu, G. Fan and J. Liu, Chem. Commun., 2020, Advance Article , DOI: 10.1039/D0CC00513D

Social activity

Search articles by author

Spotlight

Advertisements